Desvenlafaxine
Product Images NDC 53002-1801

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 53002-1801). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Image 1)

Chemical structure of desvenlafaxine hydrate showing the molecular arrangement including hydroxyl groups, a dimethylaminoethyl side chain, and an associated succinate moiety with water of hydration.*

FDA Label Image

1 (Image 2)

A chart depicting geometric mean ratios (90% confidence intervals) for pharmacokinetic parameters Cmax and AUC under varying conditions including renal impairment (mild, moderate, severe, ESRD), hepatic impairment (mild, moderate, severe), and population descriptions by gender and age groups (65-75 years, >75 years). The horizontal axis shows change relative to reference values, with data points and confidence intervals illustrated for each condition.*

FDA Label Image

1 (Image 3)

A chart showing the geometric mean ratio (90% confidence interval) of pharmacokinetic changes due to CYP3A4 inhibitors, specifically ketoconazole. It compares Cmax and AUC values relative to the reference, with Cmax around 1.08 and AUC around 1.43, including confidence intervals.*

FDA Label Image

3 (Image 4)

A pharmacokinetic chart illustrating the geometric mean ratio (90% confidence interval) of changes in Cmax and AUC values for Desvenlafaxine ER Tablets at 50mg, 100mg, and 400mg strengths when coadministered with interacting drugs including Desipramine, Midazolam, Tamoxifen, and Aripiprazole. The chart compares these values against a reference baseline to show drug interaction effects on absorption and metabolism.*

FDA Label Image

Figure 4 (Image 5)

A Kaplan-Meier survival curve graph showing the estimated proportion of patients with relapse (%) over time in days from randomization. The graph compares Desvenlafaxine Extended-Release Tablets 50 mg versus placebo, illustrating time to relapse.*

FDA Label Image

Figure 5 (Image 6)

A Kaplan-Meier curve illustrating the estimated proportion of patients with relapse over time in days from randomization. The graph compares relapse rates between patients treated with Desvenlafaxine Extended-Release Tablets and those given placebo, showing a time-to-relapse analysis up to approximately 180 days.*

FDA Label Image

Label Image (Lbl530021801)

Desvenlafaxine 50 mg extended-release tablets in a patient medication blister pack from RPK Pharmaceuticals, Inc. The label instructs a dosage of one tablet daily. The packaging includes a lot number, expiration date, barcodes, and spaces for patient and prescribing information. It contains 30 tablets per pack.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.